(Q35617600)

9 August 2017

1 reference

title

Mifepristone for luteal phase contraception (English)

1 reference

9 August 2017

1 reference

1 reference

Horacio B Croxatto

1

1 reference

9 August 2017

publication date

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

68

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

483-488

1 reference

Early luteal phase treatment with mifepristone (RU 486) for fertility regulation

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Feasibility of administering mifepristone as a once a month contraceptive pill

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Contraceptive efficacy of low doses of mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Contraceptive efficacy of daily administration of 0.5 mg mifepristone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Effect of long-term treatment with low-dose mifepristone on the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Mifepristone as a late post-coital contraceptive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

A randomized double-blind comparison of two single doses of mifepristone for emergency contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Interception. III: Postcoital luteal contragestion by an antiprogestin (mifepristone, RU 486) in 62 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Interception. IV: Failure of mifepristone (RU 486) as a monthly contragestive, "Lunarette"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Late postcoital treatment against pregnancy with antiprogesterone RU 486

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Contragestion with late luteal administration of RU 486 (Mifepristone)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Effect of mifepristone and levonorgestrel on expression of steroid receptors in the human Fallopian tube

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Progesterone receptor isoform B in the human fallopian tube and endometrium following mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Effects of a single post-ovulatory dose of RU486 on endometrial maturation in the implantation phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

The effect of a single dose of mifepristone (RU486) on the fine structure of the human endometrium during the early luteal phase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

A multiparametric analysis of endometrial estrogen and progesterone receptors after the postovulatory administration of mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

The effect of various doses of mifepristone on endometrial leukaemia inhibitory factor expression in the midluteal phase--an immunohistochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

The effects of the antiprogesterone RU486 (Mifepristone) on an endometrial secretory glycan: an immunocytochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Emergency contraception with mifepristone and levonorgestrel: mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

The effect of antiprogestin on integrin expression in human endometrium: an immunohistochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Expression of cyclo-oxygenase in human endometrium during the implantation period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2 alpha concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

Hormone regulation and hormone antagonist effects on protein patterns of human endometrial secretion during receptivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900182-3

10.1016/S0010-7824(03)00182-3

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference